Announcement • Apr 30
China NT Pharma Group Company Limited, Annual General Meeting, Jun 04, 2026 China NT Pharma Group Company Limited, Annual General Meeting, Jun 04, 2026, at 11:00 China Standard Time. Location: unit 2102, 21/f, west tower, shun tak centre, 168-200 connaught road central, Hong Kong New Risk • Apr 28
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Hong Kong stocks, typically moving 10% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Negative equity (-CN¥274m). Shareholders have been substantially diluted in the past year (41% increase in shares outstanding). Minor Risks Share price has been volatile over the past 3 months (10% average weekly change). Revenue is less than US$5m (CN¥24m revenue, or US$3.5m). Market cap is less than US$100m (HK$616.8m market cap, or US$78.7m). Reported Earnings • Apr 02
Full year 2025 earnings released: CN¥0.84 loss per share (vs CN¥0.20 loss in FY 2024) Full year 2025 results: CN¥0.84 loss per share. Net loss: CN¥26.0m (loss narrowed 51% from FY 2024). Announcement • Mar 26
China NT Pharma Group Company Limited (SEHK:1011) completed the acquisition of 58.11% stake in Zhejiang Kangyuan Medical Equipment Co., Ltd from a group of shareholders. China NT Pharma Group Company Limited (SEHK:1011) entered into a sale and purchase agreement to acquire 58.11% stake in Zhejiang Kangyuan Medical Equipment Co., Ltd from a group of shareholders for approximately CNY 100 million on April 28, 2025. The consideration consists of 274.75 million common equity of China NT Pharma Group Company Limited to be issued for common equity of Zhejiang Kangyuan Medical Equipment Co., Ltd.
For the period ending December 31, 2024, Zhejiang Kangyuan Medical Equipment Co., Ltd reported total revenue of CNY 1.81 million and net loss of CNY 3.07 million.
The transaction is subject to approval of offer by acquirer board and shareholders, approval by regulatory board / committee and listing / approval of new shares on stock exchange. As of December 24, 2025, the transaction has been recommended by the board of China NT Pharma Group Company Limited. As of December 24, 2025, the long stop date is on April 28, 2026. As of January 15, 2026, the transaction has been approved by the shareholders of China NT Pharma Group Company Limited.
China NT Pharma Group Company Limited (SEHK:1011) completed the acquisition of 58.11% stake in Zhejiang Kangyuan Medical Equipment Co., Ltd from a group of shareholders on March 25, 2026. New Risk • Mar 26
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 41% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Negative equity (-CN¥277m). Shareholders have been substantially diluted in the past year (41% increase in shares outstanding). Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Revenue is less than US$5m (CN¥19m revenue, or US$2.7m). Market cap is less than US$100m (HK$673.8m market cap, or US$86.2m). New Risk • Mar 24
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Negative equity (-CN¥277m). Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Revenue is less than US$5m (CN¥19m revenue, or US$2.7m). Market cap is less than US$100m (HK$485.5m market cap, or US$62.0m). Announcement • Mar 18
China NT Pharma Group Company Limited to Report Fiscal Year 2025 Results on Mar 31, 2026 China NT Pharma Group Company Limited announced that they will report fiscal year 2025 results on Mar 31, 2026 Announcement • Feb 10
China NT Pharma Group Company Limited announced that it expects to receive HKD 65 million in funding China NT Pharma Group Company Limited announced a private placement and entered into a subscription agreement to issue unsecured convertible bonds for aggregate gross proceeds of HKD 65,000,000 on February 9, 2026. The bonds are convertible into share at a conversion price of HKD 0.64 per share. Closing of the Bonds Issue is subject to the fulfillment and/or waiver (as the case may be) of the Closing Conditions set out in the Subscription Agreements and therefore the Bonds Issue may or may not proceed. One of the investors is is a limited company incorporated under the laws of the People’s Republic of China and is principally engaged in investments in the healthcare industry subscribing for HKD 50,000,000. Another Investor is an individual who is a merchant subscribing for HKD 15,000,000. The transaction is subject to the approval of the listing committee of the Stock Exchange. The maturity date of the bonds will be the later of the date falling twenty-four (24) months from the issuance date of the Bonds; or if that is not a Business Day, on the first Business Day thereafter. The bonds will carry an Interest rate of 5% per annum payable semi-annually in arrears. The transaction is expected to close on June 30, 2026. Total Net proceeds from the offering would amount to HKD 64,000,000. Announcement • Oct 20
China Nt Pharma Group Company Limited Announces Resignation of Cheng Cheung King as Company Secretary, Effective October 17, 2025 China NT Pharma Group Company Limited announces that Mr. Cheng Cheung King ("Mr. Cheng") tendered his resignation (the "Resignation") as the company secretary of the Company with effect from 17 October 2025. New Risk • Sep 09
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -CN¥23m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CN¥23m free cash flow). Share price has been highly volatile over the past 3 months (17% average weekly change). Negative equity (-CN¥277m). Shareholders have been substantially diluted in the past year (155% increase in shares outstanding). Minor Risks Significant insider selling over the past 3 months (HK$4.2m sold). Revenue is less than US$5m (CN¥19m revenue, or US$2.6m). Reported Earnings • Sep 09
First half 2025 earnings released: CN¥0.03 loss per share (vs CN¥0.003 profit in 1H 2024) First half 2025 results: CN¥0.03 loss per share (down from CN¥0.003 profit in 1H 2024). Net loss: CN¥16.9m (down CN¥17.6m from profit in 1H 2024). Over the last 3 years on average, earnings per share has increased by 58% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth. Reported Earnings • Aug 11
First half 2025 earnings released: CN¥0.03 loss per share (vs CN¥0.003 profit in 1H 2024) First half 2025 results: CN¥0.03 loss per share (down from CN¥0.003 profit in 1H 2024). Net loss: CN¥16.9m (down CN¥17.6m from profit in 1H 2024). Over the last 3 years on average, earnings per share has increased by 57% per year but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings. Announcement • Jul 29
China NT Pharma Group Company Limited to Report First Half, 2025 Results on Aug 08, 2025 China NT Pharma Group Company Limited announced that they will report first half, 2025 results on Aug 08, 2025 Announcement • Apr 30
China NT Pharma Group Company Limited, Annual General Meeting, Jun 30, 2025 China NT Pharma Group Company Limited, Annual General Meeting, Jun 30, 2025, at 11:00 China Standard Time. Location: unit 2102, 21/f, west tower, shun tak centre, 168-200 connaught road central, Hong Kong Announcement • Apr 29
China NT Pharma Group Company Limited (SEHK:1011) agreed to acquire 58.11% stake in Zhejiang Kangyuan Medical Equipment Co., Ltd from a group of shareholders for approximately CNY 100 million. China NT Pharma Group Company Limited (SEHK:1011) agreed to acquire 58.11% stake in Zhejiang Kangyuan Medical Equipment Co., Ltd from a group of shareholders for approximately CNY 100 million on April 28, 2025. The consideration consists of 274.75 million common equity of China NT Pharma Group Company Limited to be issued for common equity of Zhejiang Kangyuan Medical Equipment Co., Ltd.
For the period ending December 31, 2024, Zhejiang Kangyuan Medical Equipment Co., Ltd reported total revenue of CNY 1.81 million and net loss of CNY 3.07 million. New Risk • Apr 22
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Hong Kong stocks, typically moving 15% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (15% average weekly change). Negative equity (-CN¥399m). Shareholders have been substantially diluted in the past year (155% increase in shares outstanding). Minor Risk Market cap is less than US$100m (HK$252.8m market cap, or US$32.6m). Reported Earnings • Apr 02
Full year 2024 earnings released: CN¥0.20 loss per share (vs CN¥0.17 loss in FY 2023) Full year 2024 results: CN¥0.20 loss per share (further deteriorated from CN¥0.17 loss in FY 2023). Revenue: CN¥38.0m (up 415% from FY 2023). Net loss: CN¥53.4m (loss widened 59% from FY 2023). Over the last 3 years on average, earnings per share has increased by 68% per year but the company’s share price has fallen by 29% per year, which means it is significantly lagging earnings. Announcement • Mar 20
China NT Pharma Group Company Limited to Report Fiscal Year 2024 Results on Mar 31, 2025 China NT Pharma Group Company Limited announced that they will report fiscal year 2024 results on Mar 31, 2025 New Risk • Mar 01
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 155% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Negative equity (-CN¥346m). Shareholders have been substantially diluted in the past year (155% increase in shares outstanding). Minor Risks Revenue is less than US$5m (CN¥31m revenue, or US$4.3m). Market cap is less than US$100m (HK$134.8m market cap, or US$17.3m). New Risk • Nov 14
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: HK$73.9m (US$9.50m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (21% average weekly change). Negative equity (-CN¥346m). Market cap is less than US$10m (HK$73.9m market cap, or US$9.50m). Minor Risk Revenue is less than US$5m (CN¥31m revenue, or US$4.3m). Reported Earnings • Oct 05
First half 2024 earnings released: EPS: CN¥0.003 (vs CN¥0.021 loss in 1H 2023) First half 2024 results: EPS: CN¥0.003 (up from CN¥0.021 loss in 1H 2023). Revenue: CN¥31.3m (up 325% from 1H 2023). Net income: CN¥661.0k (up CN¥5.46m from 1H 2023). Profit margin: 2.1% (up from net loss in 1H 2023). Over the last 3 years on average, earnings per share has increased by 61% per year but the company’s share price has fallen by 23% per year, which means it is significantly lagging earnings. Announcement • Aug 20
China NT Pharma Group Company Limited to Report Q2, 2024 Results on Aug 30, 2024 China NT Pharma Group Company Limited announced that they will report Q2, 2024 results on Aug 30, 2024 Announcement • May 01
China NT Pharma Group Company Limited, Annual General Meeting, Jun 28, 2024 China NT Pharma Group Company Limited, Annual General Meeting, Jun 28, 2024, at 11:00 China Standard Time. Location: Suite 36123613, 36/F COSCO Tower 183 Queen's Road Central Hong Kong China Agenda: To receive and adopt the audited consolidated financial statements of the Company and the reports of the directors and auditors for the year ended 31 December 2023; to re-elect the following retiring directors of the Company: to authorize the board of directors to fix the remuneration of the directors of the Company; to consider the re-appointment of Moore CPA Limited as the auditors of the Company and to authorize the board of directors of the Company to fix their remuneration; and to consider other related matters. New Risk • Apr 06
New minor risk - Revenue size The company makes less than US$5m in revenue. Total revenue: CN¥7.4m (US$1.0m) This is considered a minor risk. Companies with a small amount of revenue are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (19% average weekly change). Negative equity (-CN¥340m). Market cap is less than US$10m (HK$58.1m market cap, or US$7.42m). Minor Risks Shareholders have been diluted in the past year (11% increase in shares outstanding). Revenue is less than US$5m (CN¥7.4m revenue, or US$1.0m). Reported Earnings • Mar 30
Full year 2023 earnings released: CN¥0.017 loss per share (vs CN¥0.035 loss in FY 2022) Full year 2023 results: CN¥0.017 loss per share (improved from CN¥0.035 loss in FY 2022). Net loss: CN¥33.5m (loss narrowed 50% from FY 2022). Over the last 3 years on average, earnings per share has increased by 45% per year but the company’s share price has fallen by 46% per year, which means it is significantly lagging earnings. New Risk • Mar 26
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: HK$55.5m (US$7.09m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (19% average weekly change). Negative equity (-CN¥248m). Market cap is less than US$10m (HK$55.5m market cap, or US$7.09m). Minor Risk Shareholders have been diluted in the past year (11% increase in shares outstanding). Announcement • Mar 20
China NT Pharma Group Company Limited to Report Fiscal Year 2023 Results on Mar 28, 2024 China NT Pharma Group Company Limited announced that they will report fiscal year 2023 results on Mar 28, 2024 Buy Or Sell Opportunity • Mar 12
Now 31% undervalued after recent price drop Over the last 90 days, the stock has fallen 46% to HK$0.037. The fair value is estimated to be HK$0.053, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has grown by 50%. Buy Or Sell Opportunity • Jan 31
Now 31% undervalued after recent price drop Over the last 90 days, the stock has fallen 51% to HK$0.034. The fair value is estimated to be HK$0.05, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has grown by 50%. Board Change • Jan 21
Less than half of directors are independent Following the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Non-Executive Director Ming Kwan Ng was the last independent director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Announcement • Jan 15
China Nt Pharma Group Company Limited Announces Board Changes The board of directors of China NT Pharama Group Company Limited announced the following changes in composition of the Board. REDESIGNATION OF DIRECTOR: Ms. Chin Yu ("Ms. Chin") will be re-designated from an executive Director to a non-executive Director with effect from 15 January 2024. Ms. Chin, co-founder of the Group. She has been an executive Director since February 2015 and responsible for the Group's daily operations. Ms. Ng, Anna Ching Mei ("Ms. Ng") has been appointed as an executive Director of the Company with effect from 15 January 2024. She is the daughter of Mr. Ng and Ms. Chin, a executive Director, co-founder of the Group and the substantial shareholder of the Company. She also is niece of Dr. Qian Wei, a non-executive Director. The biographical details of Ms. Ng is set out below: Ms. Ng, age 25, graduated from MSc Healthcare at University College London. She has 3 years working experience on laboratory experimental research with professor in Medicine and Biological Information Engineering department of Northeastern University Shenyang China. Ms. Ng has published 2 journals on Chinese Academy of Sciences and declared the exclusive right by The China national patent office of these journals. Ms. Ng has ample experience in medicine and biological information engineering. Announcement • Dec 29
China NT Pharma Group Company Limited Announces Change of Company Secretary, Effective 31 December 2023 The board of directors of China NT Pharma Group Company Limited announced that Mr. Pang Wing Hong (‘Mr. Pang’) tendered his resignation (the ‘Resignation’) as the company secretary of the Company, the authorised representative of the Company (the ‘Authorised Representative’) under Rule 3.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the ‘Stock Exchange’) (the ‘Listing Rules’) and the agent for the acceptance of service of process and notices on behalf of the Company in Hong Kong under Rule 19.05(2) of the Listing Rules and Part 16 of the Companies Ordinance (Chapter 622 of the Laws of Hong Kong) (the ‘Process Agent’) with effect from 31 December 2023. Mr. Pang confirmed that he has no disagreement with the Board and there are no circumstances related to his Resignation which need to be brought to the attention of the Stock Exchange and the shareholders of the Company. The Board is also announced that Mr. Cheng Cheung King (‘Mr. Cheng’) has been appointed in replacement of Mr. Pang as the company secretary of the Company the Authorised Representative and the Process Agent with effect from 31 December 2023. Mr. Cheng, aged 34, holds a Bachelor's degree in Accounting from the University of Adelaide in Australia and a Master degree of Corporate Governance from The Hong Kong Polytechnic University. Mr. Cheng is a certified public accountant of CPA Australia and an associate member of both the Chartered Governance Institute and The Hong Kong Chartered Governance Institute. With over 10 years of experience in the fields of accounting, auditing, and company secretarial work, Mr. Cheng has held various senior positions in the past 5 years, including finance manager and financial controller in a Main Board listed company and a Pre-IPO company, respectively. New Risk • Oct 06
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Hong Kong stocks, typically moving 15% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (15% average weekly change). Negative equity (-CN¥248m). Minor Risks Shareholders have been diluted in the past year (39% increase in shares outstanding). Market cap is less than US$100m (HK$184.9m market cap, or US$23.6m). Reported Earnings • Sep 06
First half 2023 earnings released: CN¥0.002 loss per share (vs CN¥0.015 loss in 1H 2022) First half 2023 results: CN¥0.002 loss per share (improved from CN¥0.015 loss in 1H 2022). Revenue: CN¥82.6m (down 31% from 1H 2022). Net loss: CN¥5.61m (loss narrowed 80% from 1H 2022). Over the last 3 years on average, earnings per share has increased by 50% per year but the company’s share price has fallen by 17% per year, which means it is significantly lagging earnings. Announcement • Aug 10
China NT Pharma Group Company Limited to Report First Half, 2023 Results on Aug 31, 2023 China NT Pharma Group Company Limited announced that they will report first half, 2023 results on Aug 31, 2023 Board Change • Jan 26
High number of new directors Independent Non-Executive Director Ming Kwan Ng was the last director to join the board, commencing their role in 2023. Announcement • Jan 20
China Nt Pharma Group Company Limited Announces Change of Independent Non-Executive Director and Member of Audit Committee The board of directors of China NT Pharma Group Company Limited announced that Mr. Pan Fei ("Mr. Pan") has resigned as an independent non-executive director and a chairman of the Audit Committee of the Company with effect from 19 January 2023 in order to devote more time on his other personal matters andcommitments. Mr. Pan has confirmed that he has no disagreement with the Board and there is no matter in relation to his resignation that needs to be brought to the attention of the shareholders of the Company or the Stock Exchange. The Board announce that Mr. Ng Ming Kwan ("Mr. Ng") has been appointedas an independent non-executive director of the Company and a chairman of the Audit Committee of the Company, all with effect from 19 January 2023. The biographical details of Mr. Ng are set out below. Mr. Ng, aged 45, has over 20 years of experience in financial management, accounting and corporate finance. He obtained a Bachelor of Business Administration degree from Richard Ivey School of Business, University of Western Ontario in 2000. He is a certified public accountant of the Hong Kong Institute of Certified Public Accountants, a Chartered Professional Accountants of Canada and a Certified Management Accountants of Canada. Mr.Ng has been the chief financial officer of Milestone Builder Holdings Limited, a company listed on the Main Board of The Stock Exchange of Hong Kong Limited (the "Stock Exchange") since March 2021. Pursuant to the letter of appointment entered into between Mr. Ng and the Company, the term of appointment of Mr. Ng will be for an initial term of three years commencing from 19 January 2023, subject to the retirement by rotation and re-election provisions in the bye-laws and articles of association of the Company. Reported Earnings • Oct 03
First half 2022 earnings released: CN¥0.015 loss per share (vs CN¥0.001 loss in 1H 2021) First half 2022 results: CN¥0.015 loss per share (further deteriorated from CN¥0.001 loss in 1H 2021). Revenue: CN¥120.5m (up 8.3% from 1H 2021). Net loss: CN¥28.2m (loss widened CN¥25.6m from 1H 2021). Over the last 3 years on average, earnings per share has increased by 61% per year but the company’s share price has fallen by 44% per year, which means it is significantly lagging earnings. Reported Earnings • Sep 02
First half 2022 earnings released: CN¥0.015 loss per share (vs CN¥0.001 loss in 1H 2021) First half 2022 results: CN¥0.015 loss per share (down from CN¥0.001 loss in 1H 2021). Revenue: CN¥120.5m (up 8.3% from 1H 2021). Net loss: CN¥28.2m (loss widened CN¥25.6m from 1H 2021). Over the last 3 years on average, earnings per share has increased by 61% per year but the company’s share price has fallen by 43% per year, which means it is significantly lagging earnings. Announcement • Aug 25
China NT Pharma Group Company Limited Announces Resignation of Wu Weizhong as Executive Director and Senior Vice President The board of directors of China NT Pharma Group Company Limited announced that Mr. Wu Weizhong has tendered his resignation as an executive Director of the Company and senior vice president of the Group with effect from 24 August 2022 for the reason that he wishes to spend more time on the main operation of the Group's wholly-owned subsidiary. Mr. Wu remains as an executive director and his positions of Suzhou First Pharmaceutical Co., Ltd, a limited liability company established in the PRC and a wholly-owned subsidiary of the Company. Mr. Wu has confirmed that there is no disagreement with the Board and there is no matter relating to his resignation that need to be brought to the attention of the shareholders of the Company or The Stock Exchange of Hong Kong Limited. Announcement • Aug 06
China NT Pharma Group Company Limited to Report First Half, 2022 Results on Aug 31, 2022 China NT Pharma Group Company Limited announced that they will report first half, 2022 results on Aug 31, 2022 Board Change • Jun 20
Less than half of directors are independent Following the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Non-Executive Director Fei Pan was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Jun 04
Full year 2021 earnings released: CN¥0.079 loss per share (vs CN¥0.10 loss in FY 2020) Full year 2021 results: CN¥0.079 loss per share (up from CN¥0.10 loss in FY 2020). Revenue: CN¥226.7m (up 2.2% from FY 2020). Net loss: CN¥149.5m (loss narrowed 21% from FY 2020). Over the last 3 years on average, earnings per share has increased by 63% per year but the company’s share price has fallen by 38% per year, which means it is significantly lagging earnings. Announcement • May 31
China NT Pharma Group Company Limited, Annual General Meeting, Jun 30, 2022 China NT Pharma Group Company Limited, Annual General Meeting, Jun 30, 2022, at 11:00 China Standard Time. Location: No. 1 HuaLing Road, SuZhou Industrial Park Suzhou China Agenda: To receive and adopt the audited consolidated financial statements of the Company and the reports of the directors and auditors for the year ended 31 December 2021; to consider directorate reelections; to consider the re-appointment of Crowe (HK) CPA Limited as the auditors of the Company and to authorise the board of directors of the Company to fix their remuneration; and to consider other matters. Announcement • May 07
China NT Pharma Group Company Limited to Report Q1, 2022 Results on May 20, 2022 China NT Pharma Group Company Limited announced that they will report Q1, 2022 results on May 20, 2022 Reported Earnings • Apr 03
Full year 2021 earnings released: EPS: CN¥0 (vs CN¥0.10 loss in FY 2020) Full year 2021 results: EPS: CN¥0 (up from CN¥0.10 loss in FY 2020). Revenue: CN¥226.7m (up 2.2% from FY 2020). Net loss: CN¥542.0k (loss narrowed 100% from FY 2020). Over the last 3 years on average, earnings per share has increased by 73% per year but the company’s share price has fallen by 54% per year, which means it is significantly lagging earnings. Reported Earnings • Sep 05
First half 2021 earnings released: CN¥0.001 loss per share (vs CN¥0.025 loss in 1H 2020) The company reported a solid first half result with reduced losses, improved revenues and improved control over expenses. First half 2021 results: Revenue: CN¥111.2m (up 24% from 1H 2020). Net loss: CN¥2.65m (loss narrowed 94% from 1H 2020). Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has fallen by 61% per year, which means it is significantly lagging earnings. Announcement • Aug 28
China NT Pharma Group Company Limited Provides Group Earnings Guidance for the Six Months Ended 30 June 2021 China NT Pharma Group Company Limited provided group earnings guidance for the six months ended 30 June 2020. The Board announced the Shareholders and potential investors that, based on the information currently available, the Board expects to record a significant increase in revenue by approximately 25% for the six months ended 30 June 2021 as compared to the revenue for the six months ended 30 June 2020; and the Board expects to record a significant decrease in net loss by approximately 80% for the six months ended 30 June 2021 as compared to the net loss for the six months ended 30 June 2020. Reported Earnings • Apr 02
Full year 2020 earnings released The company reported a decent full year result with reduced losses and improved control over expenses, although revenues were weaker. Full year 2020 results: Revenue: CN¥221.7m (down 39% from FY 2019). Net loss: CN¥189.0m (loss narrowed 68% from FY 2019). Announcement • Mar 19
China NT Pharma Group Company Limited to Report Fiscal Year 2020 Results on Mar 31, 2021 China NT Pharma Group Company Limited announced that they will report fiscal year 2020 results on Mar 31, 2021 Reported Earnings • Oct 01
First half earnings released Over the last 12 months the company has reported total losses of CN¥590.9m, with losses narrowing by 21% from the prior year. Total revenue was CN¥361.4m over the last 12 months, up 2.3% from the prior year. Announcement • Jul 18
China NT Pharma Group Company Limited to Report First Half, 2020 Results on Aug 28, 2020 China NT Pharma Group Company Limited announced that they will report first half, 2020 results on Aug 28, 2020